Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

Cebix Incorporated72 enrolled

Overview

The purpose of this study is to assess safety and tolerability and determine the pharmacokinetics of subcutaneous single and multiple (up to 12) dose administration of CBX129801 (long-acting synthetic C-peptide) in type 1 diabetes patients.

This study will be conducted in two parts (Part 1 and Part 2). Part 1 will be conducted in three sequential dose cohorts with dose level escalated for each successive cohort. In Part 2 of the study, a dose regimen determined from the pharmacokinetic data from Part 1 will be administered in up to 40 additional subjects to achieve a target plasma concentration range that represents the most commonly observed physiological C-peptide levels in healthy, non-diabetic individuals.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Type 1 Diabetes Diabetes Mellitus Peripheral Diabetic Neuropathy

Interventions

CBX129801DRUG

Subcutaneous injection

PlaceboDRUG

Subcutaneous injection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Give informed consent * Aged 18 to 55 years (Part 1), Ages 18 to 65 years (Part 2) * Stable type 1 diabetes mellitus (T1DM) for a minimum of 5 years * Body mass index of 18-35 kg/m2 * Be C-peptide deficient (assessed by fasting concentration level) * Normal renal function (assessed by serum creatinine) * Be in good general health (besides T1DM) * Have abnormal sural nerve conduction velocity observed bilaterally (Part 2 only) Key Exclusion Criteria: * Any significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine (except for diabetes mellitus), central nervous, or gastrointestinal condition or disease * Unstable glucose control * Have had a islet cell, kidney, and/or pancreas transplant * Blood loss or blood donation within 56 days * Drug or alcohol abuse (within 2 years) or recreational drug use (within 3 months) * History or positive test result for Hepatitis B, C, and/or HIV * Treatment with medication for peripheral neuropathy within 30 days

Locations (8)

Unnamed facility

Escondido, California, United States

Unnamed facility

Tustin, California, United States

Unnamed facility

Walnut Creek, California, United States

Unnamed facility

Aurora, Colorado, United States

Outcomes

Primary Outcomes

To assess the single and multiple dose pharmacokinetics of plasma CBX129801 after subcutaneous (SC) administration of CBX129801 by estimating parameters of Cmax, Tmax, Cmin, AUClast, AUCinf, Tlag, Cav, CL/F, Vz/F, and half life.

Plasma CBX129801 will be used to assess the concentration versus time profiles and PK of CBX129801.

Time frame: For duration of study / 16 months

To assess the safety and tolerability of CBX129801 when administered SC by adverse events, injection site assessments, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms.

Time frame: For duration of study / 16 months

Secondary Outcomes

To evaluate the technique of sensory nerve conduction velocity (SNCV) in the sural nerves in patients with type 1 diabetes mellitus.

Time frame: Predose and 6 and 12 weeks postdose

To assess the immunogenicity of CBX129801 by occurrence of anti-CBX129801 antibody formation.

Time frame: For duration of study / 16 months

To evaluate the technique of motor nerve conduction velocity (MNCV) in the peroneal nerves in patients with type 1 diabetes mellitus.

Time frame: Predose and 6 and 12 weeks postdose

To evaluate the technique of vibration perception threshold (VPT) in patients with type 1 diabetes (Part 2 only)

Time frame: Predose and 12 weeks postdose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.